OraSure Reports Q3 Revenue Growth, Provides Q4 Revenue Guidance

OraSure Technologies reported total net revenues of $30.9 million for the third quarter of 2026, representing a 14% increase year-over-year. Core revenues, excluding COVID-19 and Risk Assessment Testing, also grew by 14% compared to the prior year. Diagnostics revenues rose 16% to $16.8 million, driven by higher HIV and HCV revenues and the inclusion of BioMedomics' Sickle SCAN sales, while Sample Management Solutions revenues increased 21% to $12.5 million. The company achieved a GAAP gross margin of 45.2%, up from 43.5% in the same period last year, attributed to operational efficiencies.

Looking ahead, OraSure provided guidance for fourth-quarter 2026 total revenues between $30.0 million and $32.0 million.